NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that results from its Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE